LOXO
E561034
LOXO was the stock ticker symbol for Loxo Oncology, a biopharmaceutical company focused on developing targeted cancer therapies before its acquisition.
Observed surface forms (3)
| Surface form | Occurrences |
|---|---|
| Loxo Oncology | 0 |
| larotrectinib | 0 |
| selpercatinib | 0 |
Statements (27)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
cancer drug ⓘ public company ⓘ stock ticker symbol ⓘ |
| acquiredBy | Eli Lilly and Company NERFINISHED ⓘ |
| acquisitionAnnouncedOn | 2019-01-07 ⓘ |
| acquisitionCompletedIn | 2019 ⓘ |
| acquisitionValueUSD | 8000000000 ⓘ |
| businessModel | development of small molecule inhibitors ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| focus |
oncology
ⓘ
targeted cancer therapies ⓘ |
| foundedBy | Joshua Bilenker NERFINISHED ⓘ |
| headquartersLocation | Stamford, Connecticut NERFINISHED ⓘ |
| indication |
RET-altered cancers
ⓘ
solid tumors with NTRK gene fusions ⓘ |
| industry | biotechnology ⓘ |
| notableDrugCandidate |
larotrectinib
NERFINISHED
ⓘ
selpercatinib NERFINISHED ⓘ |
| parentCompanyAfterAcquisition | Eli Lilly and Company NERFINISHED ⓘ |
| represents | Loxo Oncology NERFINISHED ⓘ |
| researchArea |
genomically defined cancers
ⓘ
precision oncology ⓘ |
| stockExchange | NASDAQ ⓘ |
| target |
RET kinase
NERFINISHED
ⓘ
TRK fusion proteins ⓘ |
| tickerSymbol | LOXO NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology